You must log in or register to comment.
Click save:
It’s a progressive auto immune disease involving the lungs that was previously less common and limited to mainly Asian populations.
I think it's important to note that it causes PULMONARY FIBROSIS.
Sixty new anti-MDA5+, but not other MSAs surged between 2020 and 2022, increasing from 0.4% in 2019 to 2.1% (2020), 4.8% (2021) and 1.7% (2022).
I'd be curious to see if it improved in 2023/24 or if it stayed similarly high. Also wonder what (if anything) caused the drop in 2022. Different strains, maybe?